Neurogene Inc.
- NGNE
- NASDAQ
- Biotechnology
- Gene Therapy
- Neurological Disease Treatments
- AAV9 Therapy
$24.17
Today +3.96%Quote Oct 19, 2026, 08:00 PM UTC
−28.26%over the last month
Max drawdown −35.8%From 1-month high −30.8%3 months −37.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Neurogene
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease).
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
131
Market value
$483.7M
Quote Oct 19
Floor
$22.21
8.1% below price
Resistance
$24.30
0.6% above price
Price vs analyst targets
7 analysts
Lowest target
$65.00Highest target
$81.00
$65.00Highest target
$81.00
- Price $24.17
- Average target $72.00
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 198% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about NGNEPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free